Peptides UK

Research Peptides UK Gonadorelin Peptide UK: GnRH Evidence in the Peptides UK Market Gonadorelin is the pharmaceutical and synthetic name for human gonadotrophin-releasing hormone I, commonly abbreviated to GnRH-I. It is a ten-amino-acid hypothalamic peptide that controls the pituitary release of luteinising hormone and follicle-stimulating hormone. The biological result depends critically on the pattern of exposure. Short physiological pulses stimulate reproductive hormone signalling, while sustained or excessively frequent exposure can reduce pituitary responsiveness. A prescription-only gonadorelin hydrochloride product is authorised in the UK for diagnostic...

Research Peptides UK Cagrilintide Peptide UK: Amylin Evidence in the Peptides UK Market Cagrilintide is an investigational, long-acting and lipidated analogue of human amylin. It contains 37 amino-acid residues, six substitutions designed partly to reduce fibril formation, an intramolecular disulphide bond, C-terminal amidation and a fatty-acid side chain intended to extend systemic exposure. Clinical development has examined cagrilintide as an independent weight-management candidate and in combination with semaglutide under the name CagriSema. Phase-two and phase-three studies have reported substantial average weight reductions, but cagrilintide has...

Research Peptides UK SNAP-8 Peptide UK: Acetyl Octapeptide-3 Evidence in the Peptides UK Market SNAP-8 is a cosmetic-industry trade name commonly associated with Acetyl Octapeptide-3, a synthetic peptide composed of eight amino-acid residues. It was developed as an elongated analogue of Acetyl Hexapeptide-8 and designed to imitate part of the N-terminal region of SNAP-25, a protein involved in the SNARE complex that supports neurotransmitter-containing vesicle fusion. Laboratory and manufacturer research proposes that SNAP-8 can destabilise assembly of this complex and reduce selected neurotransmitter-release measurements. Human...

Research Peptides UK ARA-290 Peptide UK: Cibinetide Evidence in the Peptides UK Market ARA-290, formally known as cibinetide, is an investigational 11-amino-acid peptide engineered to imitate part of the three-dimensional tissue-protective surface of erythropoietin. Unlike erythropoietin itself, cibinetide was designed without clinically meaningful red-blood-cell-stimulating activity. It has been investigated principally in sarcoidosis-associated small-fibre neuropathy, diabetic neuropathy, diabetic macular oedema, complex regional pain syndrome and experimental tissue-injury models. Small phase-two studies reported promising changes in neuropathic symptoms and nerve-fibre measurements, but the evidence remains preliminary, short...